CRIS — CURIS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1108205 ·
Last close
$0.83
Market Cap
$2.01M
52W High
$34.80
52W Low
$0.81
ADV30
174,177
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -9,940,000 | -8,581,000 | 18,970,000 | 5,073,000 | 14,275,000 |
| Mar 2026 | 0 | 0 | -11,519,000 | -24,199,000 | 29,686,000 | 15,001,000 | 16,979,000 |
| Dec 2025 | 1,138,000 | 1,138,000 | -7,570,000 | 19,356,000 | 19,966,000 | 5,061,000 | 14,504,000 |
| Sep 2025 | 3,176,000 | 3,161,000 | -6,924,000 | -7,729,000 | 27,641,000 | 9,051,000 | 42,332,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,950,000
Investing CF
$2,500,000
Financing CF
$21,169,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-23.80
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,271,580,000
Inventory
—
Receivables
$0
ST Investments
$0
EBIT TTM
$-6,759,000
Pretax Income TTM
$-21,165,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,314,000
EBITDA
$-35,869,000
Free Cash Flow
$-15,766,000
Enterprise Value
$-1,667,213
Total Cash
$5,073,000
Total Debt
$1,044,000
Shares Out
2,425,078
Trailing EPS
$3.65
Book Value
$2.41
ROE
-693.9%
ROA
-93.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,443,000 | -32,902,000 | -7,582,000 | 19,966,000 | 14,504,000 | 5,462,000 | -27,201,000 |
| Dec 2024 | 10,908,000 | -44,542,000 | -43,389,000 | 41,265,000 | 47,263,000 | -5,998,000 | -39,563,000 |
| Dec 2023 | 10,023,000 | -48,332,000 | -47,413,000 | 77,282,000 | 57,612,000 | 19,670,000 | -38,434,000 |
| Dec 2022 | 10,162,000 | -53,020,000 | -56,672,000 | 108,848,000 | 62,296,000 | 46,552,000 | -54,337,000 |
TTM Snapshot
Revenues TTM
$10,969,000
NetIncome TTM
$-46,183,000
OpCashFlow TTM
$0
Assets (Latest)
$19,966,000
Forward EPS
$-6.01
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABPO | Abpro Holdings, Inc. | $2.42M | $0.41 | — |
| BCAB | BioAtla, Inc. | $2.47M | $1.48 | — |
| SLXN | Silexion Therapeutics Corp | $1.45M | $0.26 | — |
| CLDI | Calidi Biotherapeutics, Inc. | $2.92M | $1.13 | — |
| VIVS | VivoSim Labs, INC. | $2.95M | $0.22 | — |
News headlines (Yahoo Finance, 1h cache)
VISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcine
2026-08-26 14:16 · Yahoo
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
2026-08-13 12:00 · Yahoo
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework
2026-08-05 17:11 · Yahoo
Curis Doses First Five Patients in TakeAim CLL Study
2026-07-30 12:00 · Yahoo
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
2026-07-27 16:30 · Yahoo
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus
2026-07-22 16:12 · Yahoo
Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)
2026-07-22 12:25 · Yahoo
Curis Announces Positive Emavusertib Update
2026-07-22 11:00 · Yahoo
Curis opens 11 sites for emavusertib combo in TakeAim CLL trial
2026-06-29 10:37 · Yahoo
Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk
2026-06-23 23:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.